Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan - Takeaways - MDSpire

Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan

  • By

  • Yuya Seko

  • Kanji Yamaguchi

  • April 15, 2026

  • 0 min

Share

  • 1

    The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan increased from 21.8% to 30.3% between 2018 and 2019.

  • 2

    Lean MASLD accounts for 20.7% of the MASLD population in Japan, highlighting its occurrence in individuals with a BMI under 23 kg/m2.

  • 3

    Non-invasive liver disease assessment methods are advancing, enabling earlier diagnosis and management of MASLD/MASH in Japan.

  • 4

    Emerging therapies for MASH, including lifestyle changes and medications like resmetirom and semaglutide, are transforming treatment strategies.

  • 5

    Challenges in managing MASLD/MASH include a lack of standardized guidelines and the need for personalized treatment approaches.

Original Source(s)

Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan

  • by Yuya Seko, Kanji Yamaguchi

  • April 15, 2026

Related Content

The Connection Between Periodontal Microbiota and Liver Disease Development: Insights into the Oral-Gut-Liver Axis

Optimizing healthcare resources in pyogenic liver abscess: a dual-threshold HDL-CRP model for predicting hospitalization duration across multi-cohorts

Mechanisms and Therapeutic Promise of Electroacupuncture for Non-Alcoholic Fatty Liver Disease